LO2A Eye Drops

Artificial tear preparation, presented in sterile, uni-dose vials to minimize risk of infection and contamination. 


LO2A is currently registered and marketed by its inventor in Germany and Switzerland for the treatment of Dry Eye Syndrome ("Dry Eye"), in Hungary for the treatment of Dry Eye and Conjunctivochalasis ("CCh") and in the Netherlands for the treatment of Dry Eye and Sjögren’s Syndrom.

LO2A was developed by Prof. Shabtay Dikstein (School of Pharmacy, Hebrew U. – 1990s), as substitute for natural tears, to lubricate and protect ocular surface tissues.

  • Well-established safety profile over more than 10 years of sales in Europe through local distributors, with no material known side effects. 

  • Preservative-free (Preservatives have recognized potential for irritation and sensitization; can damage the ocular surface and cornea)

  • Can be used with any contact lenses

  • Anti-irritant properties 

  • Non-Newtonian viscosity profile

  • Available in uni-dose and future multi-dose form

  • Wize Pharma holds exclusive marketing & distribution rights in US, ROW(*), Ukraine & Israel


Sold by the inventor as: 

  • Hylan® – Germany, the Netherlands

  • Lacrycon® – Switzerland

  • Conheal® – Hungary

Dry Eye Syndrome ("Dry Eye")

Multifactorial disease of the tear and ocular surface resulting in discomfort, visual disturbance and tear film instability with potential damage to the ocular surface.*

  • Tear layer protects the surface of the eye, providing nutrition

  • Injury is a dynamic process, resulting in change in tear composition & symptoms of burning, redness, blurred vision, etc.

  • Dry Eye is the most frequent symptom treated by ophthalmologists

  • Epidemiological studies show dry eye will occur in 14-33% of population. Market size in 2014 est. + $2.5B, increasing steadily every year. 

  • Increase in incidence with age and other factor

Conjunctivochalasis (CCh)

  • Conjunctivochalasis (CCh) is a complication of dry eye

  • Aseptic, chronic inflammation of the conjunctiva; on a background of dry eye syndrome

  • Common age-related eye condition over 50; increases in frequency &  severity with age

  • Also markedly increased in people wearing contact lenses, regardless of age

  • Appears in one third of dry eye patients

  • Inflammation condition is sustained; not spontaneously reversible

  • Severe CCh (Stage 3) can only be treated by invasive surgical treatment, which can cause considerable discomfort

Sjögren’s Syndrome

  • Sjögren’s syndrome is a chronic long-term auto-immune disease

  • The patient's white blood cells attack the saliva and tear glands, leading to dry mouth and eyes

  • While Sjögren’s syndrome can develop at any age, the majority of patients are diagnosed after the age of 40 with 90% of patients female

  • There are approximately 4,000,000 people in the USA and 500,000 in the UK with Sjögren’s Syndrome